FemTech Predictions and Trends 2026

Nelson Advisors
28 minutes ago
17 min read

Strategic Outlook 2026: The Industrialisation of FemTech and the Emergence of the Female Health Infrastructure

Executive Summary: The Pivot to Precision

The year 2026 marks the definitive conclusion of FemTech’s infancy, a period characterised by "pink" wellness apps and direct-to-consumer hygiene products and its transition into a mature, industrialised sector of the global healthcare economy. The convergence of regulatory enforcement, artificial intelligence integration, and institutional capital has fundamentally altered the trajectory of the market. What was once considered a niche vertical comprising menstrual trackers and fertility aids has expanded into a comprehensive "female health infrastructure" that underpins the economic and clinical stability of global health systems. By 2026, the global market for FemTech is valued at approximately USD $59.51 Billion, serving as a critical waypoint on a trajectory toward USD $246 Billion by 2035.

This report offers an exhaustive analysis of the FemTech landscape in 2026. It argues that the sector is defined by three structural shifts. First, the move from reactive symptom logging to proactive, biomarker-driven diagnostics, utilising novel mediums such as menstrual blood and continuous nervous system monitoring. Second, the bifurcation of the global regulatory landscape, where the European Union’s AI Act imposes strict compliance moats while the United States’ FDA TEMPO pilot incentivises rapid real-world evidence generation. Third, the transformation of investment theses from speculative venture bets on user acquisition to strategic infrastructure plays focused on longitudinal outcomes, evidenced by the multi-billion dollar valuations of platforms like Maven Clinic and the massive philanthropic interventions of the Gates Foundation.

The narrative of 2026 is one of integration. Women’s health is no longer isolated in the OB-GYN clinic; it is embedded in corporate benefit packages, prioritized in national health strategies in the UK and UAE, and encoded into the algorithms of general medical AI. This report dissects these dynamics, offering a granular view of the technological, financial, and geopolitical forces shaping the future of female health.

Macro-Economic Architecture of the FemTech Market (2026–2035)

The Expansion of the Total Addressable Market (TAM)

As the FemTech sector enters 2026, the economic definitions that once constrained it are being rewritten. Historically, market analysts confined "FemTech" to reproductive health, menstruation, fertility and maternal care. However, the 2026 landscape is defined by a broader interpretation that encompasses the entire "healthspan" of women. This includes conditions that disproportionately affect women (e.g., autoimmune diseases, migraines, osteoporosis) and conditions that manifest differently in women (e.g., cardiovascular disease, oncology). When viewed through this expanded lens, the market potential shifts from a niche segment to a fundamental pillar of the global economy, with the potential to boost the global economy by USD $1 Trillion annually by 2040 through closing the gender health gap.

Current valuations place the market at a pivotal juncture. In 2025, the market was valued at USD $51.65 billion. For 2026, estimates project a valuation of USD $59.51 billion. This growth is not linear but exponential, driven by a Compound Annual Growth Rate (CAGR) of 16.9% projected through 2035. By the mid-2030s, the market is expected to surpass USD 246 billion, driven by the commercialisation of deep-tech solutions in longevity and chronic disease management.

Global FemTech Market Valuation and Growth Trajectory (2025–2035)

Year	Estimated Market Value (USD)	Growth Context & Economic Drivers	Key Technological Catalysts
2025	$51.65 Billion	Base Year; Post-pandemic digital adoption stabilization.	Telehealth normalization, Wearable adoption.
2026	$59.51 Billion	Inflection Point; Regulatory Framework Implementation.	AI Diagnostics, Menopause Platforms, Biomarker Integration.
2030	~$130.8 Billion	Mid-term Maturation; Mass Adoption of "Clinic-at-Home."	Menstrual Blood Diagnostics, AI-driven Drug Discovery.
2033	~$206.84 Billion	Expansion; Integration into General Healthcare Infrastructure.	Precision Medicine, Longevity Therapeutics.
2035	$246.16 Billion	Long-term Saturation; Global Standard of Care.	Digital Twins, Personalized Genomic Medicine.

The acceleration witnessed in 2026 is underpinned by the "industrial logic" of private equity and institutional capital entering the space. The fragmentation of the early 2020s, characterised by thousands of disconnected apps, is resolving into a consolidated landscape of platform companies. These platforms are not merely selling subscriptions to consumers; they are selling efficiency to health systems and productivity to employers. The economic drag of untreated women's health issues, particularly regarding menopause and menstrual pain, has been quantified, transforming FemTech from a "lifestyle" purchase to a B2B (Business-to-Business) necessity.

Regional Economic Dynamics

While the aggregate numbers describe a booming sector, the distribution of value in 2026 reveals a complex geopolitical landscape. North America remains the peak in terms of deal flow and valuation, but the centre of gravity for growth rate and volume is shifting eastward.

North America: The Platform Economy

North America holds approximately 32.5% of the global FemTech market share in 2026. The region's dominance is structural; it possesses the most mature venture capital ecosystem, the highest healthcare spending per capita, and a regulatory environment that, via the FDA’s 2026 pilots, is actively encouraging digital health innovation. The US market is characterised by high-value platforms like Maven Clinic, which command valuations in the billions, and a robust "direct-to-patient" (DTP) pharmaceutical model that bypasses traditional pharmacy bottlenecks.

Asia-Pacific (APAC): The Growth Engine

The APAC region is identified as the fastest-growing market for the decade spanning 2026–2035. This growth is fueled by a convergence of demographic scale and technological "leapfrogging." In markets like China and India, where primary care infrastructure can be sparse in rural areas, mobile-first FemTech solutions are becoming the primary interface for women's health. Furthermore, the region is seeing a surge in female entrepreneurship, which is translating into products designed specifically for Asian cultural and physiological contexts. The projected revenue for the APAC FemTech market is expected to reach nearly USD $18.7 Billion by 2030, driven by rising disposable incomes and a cultural destigmatisation of reproductive health discussions.

Europe: The Regulatory Fortress

Europe represents a market in transition. In 2026, the region accounts for roughly 25.2% of global revenue.The European market is heavily influenced by the full implementation of the EU AI Act in August 2026. This regulation has created high barriers to entry, effectively filtering out low-quality "wellness" apps and favoring clinical-grade medical devices. Consequently, Europe is becoming a hub for "deep tech" FemTech, companies rooted in hard science, hardware, and rigorous clinical trials. The UK, separated from the EU regulatory block, is pursuing its own aggressive strategy with the renewal of its Women's Health Strategy, focusing on integrating FemTech into the National Health Service (NHS) to reduce waiting lists.

Middle East & North Africa (MENA): The Emerging Hub

Perhaps the most striking development in 2026 is the emergence of MENA, specifically the UAE, as a global FemTech hub. The region is projected to grow at an annual rate of 15%.This is not organic growth but strategically engineered growth. The UAE government’s focus on medical tourism and women’s rights reforms has created a safe harbor for innovation. Startups like Ovasave are leveraging this environment to digitise fertility care, capitalising on a market that was previously underserved due to cultural taboos. The MENA market is expected to reach USD $3.8 Billion by 2031, with one-third of the region's innovation concentrated in the UAE.

Technological Convergence: The Era of "Hard" Science

The overarching technological theme for FemTech in 2026 is the rejection of "soft" data (subjective symptom tracking) in favor of "hard" data (objective biomarkers). The industry has collectively realised that asking women to self-report symptoms for decades has resulted in a lack of meaningful clinical metrics. 2026 is the year this changes.

The Rise of Diagnostic Menstrual Blood

One of the most profound scientific shifts in 2026 is the reclassification of menstrual blood from medical waste to a rich diagnostic fluid. For decades, blood testing required invasive venous draws, usually performed sporadically. Menstrual fluid, however, offers a monthly, non-invasive "liquid biopsy" that contains systemic biomarkers.

Startups and research labs in 2026 are deploying smart menstrual products such as pads, cups and tampons, embedded with micro fluidic sensors or designed for sample collection. These tools allow for the analysis of:

Inflammatory Markers: Identifying cytokines associated with endometriosis years before lesions would be visible on a standard ultrasound.
Hormonal Profiles: Tracking FSH (Follicle Stimulating Hormone), LH (Luteinizing Hormone), and progesterone with quantitative precision to manage fertility and menopause.
Systemic Health Indicators: Monitoring Hemoglobin A1c for diabetes management and cholesterol levels for cardiovascular risk.

This technology fundamentally alters the user experience of menstruation. It transforms a monthly nuisance into a monthly health check-up, closing the "evidence gap" in women's health by generating longitudinal biological datasets that have never existed before.

The "Clinic-at-Home" Ecosystem

The "clinic-at-home" model has matured from a convenience to a clinical standard. In 2026, the distinction between consumer electronics and medical devices has blurred entirely.

Clinical-Grade Wearables: Devices like the Oura Ring and next-generation smartwatches are no longer just fitness trackers; they are FDA-cleared diagnostic tools. They utilise continuous monitoring of heart rate variability (HRV), body temperature, and respiratory rate to predict health events. For example, temperature trends are used to confirm ovulation with clinical accuracy, while HRV drops are used to signal physiological stress or potential pregnancy complications.
Nervous System Biomarkers: A key trend in 2026 is the focus on the autonomic nervous system. Devices now track "vagal tone" and autonomic balance to help women manage the stress-response cycle. This is particularly relevant for conditions like PMDD (Premenstrual Dysphoric Disorder) and perimenopause, where nervous system dysregulation is a core symptom. Startups like Seesaw Health are pioneering this "nervous system first" approach, moving mental health tracking beyond mood journals to physiological metrics.
Remote Maternal Monitoring: The standard of prenatal care has shifted to include continuous remote monitoring. Expectant mothers in 2026 frequently use connected devices to track blood pressure and glucose levels, feeding data directly to AI risk-assessment models. This allows for the early detection of preeclampsia and gestational diabetes, conditions that historically contributed to preventable maternal mortality.

Digital Twins and Virtual Physiology

At the cutting edge of FemTech in 2026 is the application of "digital twin" technology. This involves creating a virtual computational model of a specific patient's physiology.

Mechanism: By inputting a patient's hormonal profile, genetic data, and metabolic history, clinicians can create a "twin" to simulate treatments.
Application: This is revolutionary for complex endocrine disorders like PCOS (Polycystic Ovary Syndrome). Instead of the traditional "trial and error" approach to prescribing birth control or insulin-sensitising drugs, doctors can test the drug on the digital twin to predict efficacy and side effects.
Oncology: In breast cancer care, digital twins are used to model tumour growth and response to chemotherapy, allowing for hyper-personalised treatment plans that minimise toxicity.

Artificial Intelligence: The Nervous System of Women’s Health

If biomarkers are the fuel of FemTech in 2026, Artificial Intelligence (AI) is the engine. The integration of AI has moved beyond simple predictive algorithms (e.g., "your period starts in 2 days") to complex, generative, and diagnostic capabilities.

From Prediction to Prevention

Machine learning models in 2026 are capable of analysing vast, unstructured datasets to identify health risks before they manifest symptomatically.

Endometriosis Detection: One of the most significant breakthroughs is the use of AI in medical imaging. Algorithms trained on thousands of ultrasounds can now detect the subtle, granular tissue changes indicative of early-stage endometriosis, signs that are often invisible to the human eye during standard scans. This technology is drastically reducing the average time to diagnosis, which stood at nearly a decade in previous years.
Pregnancy Loss Prediction: Analysis of continuous biometric data (sleep quality, HRV, temperature) has revealed patterns that precede pregnancy loss or preterm labor. AI models can flag these anomalies to clinicians, allowing for potential interventions (e.g., progesterone supplementation) that were previously impossible due to a lack of real-time data.

Generative AI and the "Smart Coach"

The user interface of FemTech has been revolutionized by Generative AI (GenAI). In 2026, users interact with sophisticated health assistants rather than static FAQs.

Contextual Intelligence: These AI agents do not just report data; they interpret it. An app might tell a user, "Your luteal phase is shorter this month, which correlates with the high sleep debt and elevated cortisol levels detected last week." This contextualization transforms raw data into actionable health literacy.
Clinical Workflow: On the provider side, GenAI is alleviating the administrative burden that contributes to physician burnout. AI tools listen to patient consultations and automatically generate structured clinical notes, draft letters of medical necessity for insurance, and summarise patient histories. For radiologists, AI drafts preliminary reports for mammograms, flagging high-priority areas for human review with 95% completeness.

Ethical AI and Data Sovereignty

With the power of AI comes the peril of bias. In 2026, the industry is acutely aware of the "algorithmic bias" that arises from training models on data sets that lack diversity.

Regulatory Mandates: Under the EU AI Act, high-risk medical AI systems must prove that their training data is representative of the populations they serve. This has forced companies to diversify their clinical trials and data partnerships, ensuring that tools work equally well for women of all races and ages.
Privacy by Design: Following the reversal of Roe v. Wade in the US, data privacy is a commercial differentiator. Platforms in 2026 compete on "data sovereignty", the guarantee that sensitive reproductive data is encrypted, stored locally, or protected from third-party access. "Privacy-first personalisation" is the gold standard for user trust.

The Regulatory Landscape: A Tale of Two Continents

The regulatory environment in 2026 is defined by a divergence in approach between the European Union and the United States. This divergence influences where companies launch products and how they structure their clinical validation strategies.

The European Union: The AI Act and Compliance Moats

August 2026 marks a critical deadline: the full application of the EU AI Act for high-risk AI systems.

High-Risk Classification: The majority of medical FemTech devices, fertility predictors, diagnostic imaging AI, clinical decision support systems, fall under the "high-risk" classification.
Operational Impact: This designation triggers a suite of mandatory obligations:
- Data Governance: Strict requirements on the quality and representativeness of training data.
- Human Oversight: Systems must be designed so that human clinicians can override or interpret the AI's output.
- Technical Documentation: Exhaustive record-keeping for conformity assessments.
Strategic Consequence: These regulations create high barriers to entry. Small, unregulated "wellness" apps are being pushed out of the market or forced to pivot. Conversely, established companies that have invested in regulatory compliance (e.g., ISO 13485 certification) now possess "compliance moats" that protect them from low-quality competition. This is driving a wave of "compliance-driven M&A," where larger firms acquire startups specifically for their regulatory approvals.

The United States: The FDA TEMPO Pilot

In contrast to the EU's heavy compliance burden, the US FDA has launched a mechanism to accelerate innovation: the Technology-Enabled Meaningful Patient Outcomes (TEMPO) pilot.

Launch Timeline: The FDA began accepting statements of interest in January 2026, with the pilot operational throughout the year.
The Mechanism: The TEMPO pilot operates in conjunction with the Centers for Medicare & Medicaid Services (CMS) "ACCESS" model. It allows manufacturers of digital health devices to request enforcement discretion. This means that for specific chronic conditions (including cardio-metabolic and behavioural health issues relevant to women), companies can bypass standard premarket authorisation requirements if their device is being used within the ACCESS payment model.
The Benefit: This solves the "chicken-and-egg" problem of digital health. Usually, companies need data to get FDA clearance, but need clearance to get the data (and reimbursement). TEMPO allows them to generate Real-World Evidence (RWE) while the product is being used and reimbursed, dramatically shortening the time-to-market.
Target Areas: The pilot focuses on high-burden chronic conditions, many of which (like autoimmune disease and depression) disproportionately affect women. This provides a fast-track for FemTech companies addressing these "expanded" definitions of women's health.

The Investment Ecosystem: Capital as Infrastructure

The financial narrative of 2026 is one of maturity. The "spray and pray" venture capital tactics of the early 2020s have been replaced by concentrated bets on infrastructure-grade platforms.

Venture Capital: The Series B Cliff and Mega-Rounds

While the total volume of venture capital deployed in 2026 is expected to rise (potentially exceeding USD 400 billion globally), the distribution is highly skewed.

The Winners: Capital is flowing to late-stage companies that have proven unit economics and clinical outcomes. Maven Clinic exemplifies this trend, having secured a massive USD $125 million Series Fround, valuing the company at USD $1.7 Billion. This capital is not for experimentation; it is for scaling value-based care models in fertility and menopause.
The Struggle: Early-stage companies face a "Growth-Stage Cliff." While Seed and Series A funding is available for novel ideas (e.g., Conceivable Life Sciences raising USD 50 Million Series A for automated IVF labs), companies struggling to bridge the gap between prototype and commercial scale (Series B) face a challenging environment. Only about 2-3% of digital health growth-stage dollars are reaching women's health, forcing startups to demonstrate immediate clinical ROI.
Notable Transactions:
- Mercy BioAnalytics: Raised USD $59 Million Series B for early ovarian cancer detection, highlighting the appetite for hard science diagnostics.
- Ovasave: Secured USD $1.2 Million Pre-Seed funding to expand in the MENA region, signalling the globalisation of early-stage deals.

The Role of Philanthropy and Government

In 2026, non-dilutive funding (grants, government contracts) plays a massive role in de-risking the sector.

The Gates Foundation: A historic USD $2.5 Billion commitment through 2030 to advance R&D in women's health, specifically targeting maternal nutrition, the vaginal microbiome, and infectious diseases in low-resource settings.
Melinda French Gates: Through her organisation Pivotal, she has directed USD $250 Million in grants to women's health, reframing the issue as a prerequisite for global economic progress.
ARPA-H Sprint for Women’s Health: This US government initiative committed USD $113 Million to "spark" and "launchpad" projects. Crucially, 70% of these projects are led by women, and many are addressing "moonshot" challenges like ovarian aging and chronic pain measurement that traditional VC might deem too risky.

Clinical Vertical: Menopause and the "Silver Wave"

If fertility was the engine of FemTech 1.0, Menopause is the engine of FemTech 2.0. By 2030, over one billion women will be in perimenopause or menopause. In 2026, the industry has moved beyond "awareness" to systemic, reimbursed management.

The Economic Imperative

Employers and insurers have recognised the "She-cession", the economic loss caused by senior women leaving the workforce due to unmanaged menopause symptoms.

Benefit Adoption: In 2026, 58% of employers are expected to offer menopause-specific benefits, a dramatic increase from just 28% in 2024.
Corporate Certification: Companies are increasingly seeking "Menopause Friendly Workplace" certifications. CVS Health set the standard, and in 2026, this has become a badge of honor for retention strategies.

Tech and Therapeutics

The solutions in 2026 are diverse, ranging from digital therapeutics to hardware.

Integrated Platforms: Companies like Midi Health, Gennev, and Peppy provide comprehensive virtual clinics. They offer access to menopause-trained clinicians who can prescribe Hormone Replacement Therapy (HRT) and non-hormonal alternatives via telehealth, bridging the gap caused by the shortage of menopause specialists.
Wearable Thermostat: Hardware like Embr Labs' wristbands, which provide on-demand cooling sensations to counteract hot flashes, are being integrated into employee wellness packages.
Cognitive Support: Recognizing that "brain fog" is a primary complaint, new platforms focus on cognitive health, offering brain training and tracking cognitive biomarkers to differentiate benign menopausal changes from early signs of dementia.

Clinical Vertical: Reproductive Health and Fertility

Reproductive health remains a cornerstone of the industry, but the focus has shifted from simple tracking to "High-Resolution" fertility and complex care.

Precision Fertility

In 2026, fertility tracking involves quantitative hormone monitoring. Users confirm ovulation using at-home urine tests that measure PdG (Progesterone metabolite) and E3G, providing a clinical picture previously available only via blood draws.

Male Factor: The definition of "fertility" has expanded to include men. Startups offering at-home sperm analysis and improvement plans are increasingly integrated into FemTech platforms, acknowledging that 40-50% of infertility cases involve male factors.
Automated IVF: Companies like Conceivable Life Sciences are deploying robotics and AI to automate the IVF lab. This industrialisation of embryology aims to reduce the cost of IVF by 70%, making it accessible to a broader demographic.

Digital Contraception

Digital contraception has gone mainstream. Apps like Natural Cycles, which utilise temperature data from wearables (Oura, Apple Watch) to identify fertile windows, are FDA-cleared and widely prescribed. In 2026, the user base has expanded significantly as women seek non-hormonal alternatives to the pill. The efficacy of these algorithms, boosted by AI that filters out "bad data" (e.g., fever, alcohol consumption), rivals that of traditional hormonal methods.

Emerging Frontiers: Beyond Reproduction

A key theme of 2026 is the expansion of FemTech into general health conditions that have a specific female phenotype.

Oncology and Early Detection

The fight against breast and ovarian cancer is being aided by AI and novel diagnostics.

AI Mammography: Companies like DeepLook Medical and NeoLab AI are revolutionising breast imaging. Their FDA-cleared platforms use AI to "see through" dense breast tissue, a biological trait common in younger women that often obscures tumors on traditional mammograms. This technology is reducing false negatives and unnecessary biopsies.
Liquid Biopsy: The holy grail of ovarian cancer detection, a reliable screening test, is closer to reality. Mercy BioAnalytics is utilising its Series B funding to commercialise blood tests that detect tumour associated extracellular vesicles, offering hope for detecting this "silent killer" in early stages.

Pelvic Floor Health

Pelvic floor dysfunction, affecting one in three women, is being treated with the same rigour as orthopaedic injuries.

Gamified Therapy: Devices like Perifit and Elvie use biofeedback sensors to turn Kegel exercises into video games. In 2026, these devices are increasingly "prescribed" by physical therapists and covered by insurance as a first-line treatment for incontinence and prolapse, moving them out of the "sexual wellness" aisle and into the "medical device" category.

Regional Strategic Deep Dives

United Kingdom: The 2026 Strategy Renewal

The UK provides a case study in government-led FemTech adoption. The Women’s Health Strategy for England, renewed in 2026, sets aggressive targets.

Women's Health Hubs: The government is rolling out physical "hubs" that act as one-stop-shops for menstrual, contraceptive, and menopausal care. This physical infrastructure is supported by digital triage tools, creating a hybrid care model.
NHS Integration: The NHS app is being enhanced to include specific women's health modules. For FemTech companies, the path to scale involves securing NHS contracts, which requires rigorous evidence of cost-effectiveness (e.g., reducing GP visits).
Cervical Cancer Elimination: The UK has set a target to eliminate cervical cancer by 2040, driving demand for self-sampling HPV tests and digital screening management systems.

The UAE and MENA: A Strategic Pivot

The UAE is leveraging FemTech to modernise its healthcare system and attract medical tourism.

Startups to Watch: Ovasave (fertility/egg freezing) and Nabta Health (hybrid care for chronic conditions) are regional champions. Ovasave’s USD $1.2 Million funding round allows it to expand into Saudi Arabia, bringing digital fertility services to the Kingdom.
Policy Support: The UAE’s National Policy for Improving Women's Health prioritizes preventive care and cancer screening. The government creates a unique environment where regulatory agility allows for the rapid testing and deployment of new health technologies, making the UAE a global sandbox for FemTech innovation.

Corporate Strategy and the Future of Work

In 2026, FemTech is firmly entrenched in the corporate world. The days of "one-size-fits-all" health benefits are over.

The ROI of Women's Health Benefits

Data from 2026 shows that women's health benefits are a key driver of retention and productivity.

Retention: 69% of benefits leaders cite women's health benefits as crucial for talent acquisition.
Productivity: Providing support for menstrual pain and menopause reduces "presenteeism." Women who feel supported are 56% more engaged and significantly less likely to experience burnout.

The Benefit Stack of 2026

Forward-thinking companies are offering a "stack" of benefits that cover the lifecycle:

Family Building: Coverage for IVF, egg freezing, and adoption (providers: Carrot, Maven, Progyny).
Menopause: Access to virtual clinics and hormone therapy (providers: Midi, Peppy).
Financial Safety Nets: Insurance products like Parento that top up salaries during parental leave, ensuring that starting a family does not equate to financial penalty.
Environment: Physical changes to the office, such as "wellness rooms" for nursing or resting during severe menstrual cramps, and temperature controls for menopausal employees.

Conclusion: The Integrated Future

The FemTech landscape of 2026 is defined by its integration into the broader fabric of healthcare and society. It has successfully graduated from a niche curiosity to a burgeoning industrial sector. The drivers are clear: AI has provided the intelligence to make data actionable; regulation has provided the safety rails to build trust; and investment has provided the capital to build scale.

As we look toward 2035, the trajectory is one of "healthspan optimisation." The focus will shift increasingly toward longevity, keeping women healthy, active, and productive well into their 80s and 90s. The tools being built in 2026, the digital twins, the biomarker platforms, the regulatory pathways, are the foundation upon which this future will be built. For the first time in history, the female body is being treated not as an anomaly in medical research, but as a primary subject of innovation.

Significant FemTech Investment & Funding Events (2025-2026)

Entity / Company	Amount	Funding Type	Focus Area / Strategic Intent
Gates Foundation	$2.5 Billion	Philanthropic Commitment	Long-term R&D (thru 2030) for maternal health, nutrition, and infectious disease in low-resource settings.
Maven Clinic	$125 Million	Series F	Valuation hit $1.7 Billion. Capital used to expand value-based fertility and menopause care platforms.
ARPA-H	$113 Million	Gov. Grant	"Sprint for Women's Health" funding 70% women-led projects in ovarian health, brain health, and chronic pain.
Mercy BioAnalytics	$59 Million	Series B	Commercialization of liquid biopsy technology for the early detection of ovarian cancer.
Conceivable Life Sciences	$50 Million	Series A	Development of robotic/automated IVF labs to reduce costs and increase access to fertility treatments.
Ovasave	$1.2 Million	Pre-Seed	Expansion of digital fertility and egg-freezing services into Saudi Arabia and the broader MENA region.
Melinda French Gates	$250 Million	Grant (Pivotal)	"Action for Women's Health" initiative to improve women's mental and physical health globally.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech